Pediatric Respiratory Hospitalizations in the Pre-COVID-19 Era: The Contribution of Viral Pathogens and Comorbidities to Clinical Outcomes, Valencia, Spain

Autors de IIS La Fe
Autors aliens a IIS La Fe
- Castells, Valerie Bosch
- Mira-Iglesias, Ainara
- Lopez-Labrador, Francisco Xavier
- Mengual-Chulia, Beatriz
- Carballido-Fernandez, Mario
- Mollar-Maseres, Joan
- Puig-Barbera, Joan
- Diez-Domingo, Javier
- Chaves, Sandra S.
Grups d'Investigació
Abstract
Viral respiratory diseases place a heavy burden on the healthcare system, with children making up a significant portion of related hospitalizations. While comorbidities increase the risk of complications and poor outcomes, many hospitalized children lack clear risk factors. As new vaccines for respiratory viral diseases emerge, this study examined pediatric respiratory hospitalizations, focusing on viral etiology, complication rates, and the impact of comorbidities to guide future policy. Data were analyzed from eight pre-COVID influenza seasons (2011/2012-2018/2019) involving patients under 18 years hospitalized with respiratory complaints across 4-10 hospitals in Valencia, Spain. Respiratory specimens were tested for eight viral targets using multiplex real-time reverse-transcription polymerase chain reaction. Demographics, clinical outcomes, discharge diagnoses, and laboratory results were examined. Among the hospitalized children, 26% had at least one comorbidity. These children had higher rates of pneumonia, asthma exacerbation, and pneumothorax, and were twice as likely to require ICU admission, though mechanical ventilation and length of stay were similar to those without comorbidities. Respiratory syncytial virus (RSV) was the most common virus detected (23.1%), followed by rhinovirus/enterovirus (9.5%) and influenza (7.2%). Viral codetection decreased with age, occurring in 4.6% of cases. Comorbidities increase the risk of complications in pediatric respiratory illnesses, however, healthcare utilization is driven largely by otherwise healthy children. Pediatric viral vaccines could reduce this burden and should be further evaluated.
Dades de la publicació
- ISSN/ISSNe:
- 1999-4915, 1999-4915
- Tipus:
- Article
- Pàgines:
- -
- DOI:
- 10.3390/v16101519
- PubMed:
- 39459854
- Factor d'Impacte:
- 1,463 SCImago ℠
- Quartil:
- Q1 SCImago ℠
VIRUSES-BASEL MDPI
Documents
- No hi ha documents
Filiacions
Filiacions no disponibles
Keywords
- respiratory viruses; hospitalizations; children; comorbidities; complications; severity; viral codetection
Projectes associats
Identificación de biomarcadores inmunológicos en pacientes alérgicos.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
LET-INM-2020 . 2023
Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a Dermatophagoides pteronyssinus y/o Dermatophagoides farinae.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
MM09-SIT-023 . 2023
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA).
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
D3250C00024 . 2023
Evaluación de la eficacia y seguridad de la inmunoterapia subcutánea (Beltavac®) con extracto alergénico polimerizado de mezcla de ácaros del polvo en pacientes con rinitis/rinoconjuntivitis alérgica.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
2023
Estudio aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad a largo plazo de dupilumab en niños de 2 a <6 años con asma no controlada y/o sibilancias asmáticas graves recurrentes.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
EFC14771 . 2024
Estudio fase III multicéntrico, aleatorizado, doble ciego, de grupos paralelos y controlado con placebo de la eficacia y la seguridad de tezepelumab en niños de 5 a <12 años con asma grave no controlada (HORIZON).
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
D5180C00016 . 2024
Estudio epidemiológico de las enfermedades alérgicas pediátricas en España.
Investigador Principal: MIGUEL TORTAJADA GIRBÉS
ALERGOPEDIÁTRICA 2020 . 2024